Gilead Sciences | GILD - Заемный капитал





Заемный капитал Изменить Дата
AbbVie USD 64.53B 5.59B 2026-03
Agios Pharmaceuticals USD 1.06M 0 2022-09
ALKERMES USD 1.48B 7.23M 2026-06
Alnylam Pharmaceuticals USD 2.47B 6.56M 2026-06
Amgen USD 51.86B 27M 2026-06
Biogen USD 7.29B 1B 2026-06
BioMarin Pharmaceutical USD 3.53B 2.1B 2026-06
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Coherus Biosciences USD 51.08M 496K 2025-12
Eli Lilly USD 47.86B 8.49B 2026-06
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 13.95B 65M 2026-06
Glaxosmithkline GBP 18.53B 1.29B 2026-03
Incyte USD 28.42M 994K 2026-06
J&J USD 37.34B 183M 2026-06
Merck USD 51.08B 4.41B 2026-06
Moderna USD 597M 6M 2026-06
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 37.49B 42M 2026-06
Pfizer USD 60.5B 70M 2026-06
PTC Therapeutics USD 535.52M 248.58M 2026-06
Puma Biotechnology USD 10.87M 222K 2025-06
Regeneron Pharmaceuticals USD 1.99B 400K 2026-06
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 14.65B 806M 2026-06
Sarepta Therapeutics USD 847.62M 9.46M 2026-06
United Therapeutics USD 100M 100M 2024-06
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12